Condition: Pancreatic Adenocarcinoma · Sponsor: Aravive, Inc.
This is a Phase 1b/2 study of batiraxcept (AVB-S6-500) designed to evaluate the safety and efficacy of batiraxcept in combination with nab-paclitaxel and gemcitabine in subjects with locally advanced, recurrent, or metastatic pancreatic adenocarcinoma as first line therapy. The phase 1b portion of the study is open label and patients will receive batiraxcept, nab-paclitaxel, and gemcitabine. The Phase 2 portion of the study is randomized, 2-arm, open-label study to compare efficacy and tolerability of batiraxcept, nab-paclitaxel, and gemcitabine versus nab-paclitaxel and gemcitabine as first line therapy.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| UCLA Health | Santa Monica, California, United States | — |
| Boca Raton Regional Hospital / Lynn Cancer Institute | Boca Raton, Florida, United States | — |
| Moffit Cancer Center | Tampa, Florida, United States | — |
| University of Massachusetts Memorial Medical Center | Worcester, Massachusetts, United States | — |
| Michigan Medicine - University of Michigan | Ann Arbor, Michigan, United States | — |
| Roswell Park Comprehensive Cancer Center | Buffalo, New York, United States | — |
| Perlmutter Cancer Center at NYU Langone Health | New York, New York, United States | — |
| Duke University Medical Center (DUMC) | Durham, North Carolina, United States | — |
| Gabrail Cancer Center Research | Canton, Ohio, United States | — |
| Cleveland Clinic Foundation | Cleveland, Ohio, United States | — |
| Oregon Health and Science University | Portland, Oregon, United States | — |
| Abramson Cancer Center of the University of Pennsylvania | Philadelphia, Pennsylvania, United States | — |
+ 5 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04983407